Mutated Pathways as a Guide to Adjuvant Therapy Treatments for Breast Cancer

Abstract

Adjuvant therapy following breast cancer surgery generally consists of either a course of chemotherapy if the cancer lacks hormone receptors, or a course of hormonal therapy, otherwise. Here we report a correlation between adjuvant strategy, and mutated pathway patterns. In particular we find that for breast cancer patients, pathways enriched in non-synonymous mutations in the chemotherapy group, are distinct from those of the hormonal therapy group. We apply a recently developed method that identifies collaborative pathway groups for hormone and chemotherapy patients. A collaborative group of pathways is one in which each member is altered in the same–generally large–number of samples. In particular we find the following: (i) A chemotherapy group consisting of 3 pathways and a hormone therapy group consisting of 20, the members of the two groups being mutually exclusive. (ii) Each group is highly enriched in breast cancer drivers. (iii) The pathway groups are correlates of subtype-based therapeutic recommendations. These results suggest that patient profiling using these pathway groups can potentially enable the development of personalized treatment plans that may be more accurate and specific than those currently available.

Identification of KIF23 as a prognostic signature for ovarian cancer based on large scale samples and clinical validation

“…Some studies have shown that TNN and USH2A can be used as the most common mutant genes with predictive effect on new antigens [41]. OBSCN mutation is closely related to breast cancer and colorectal cancer [42][43]. However, the role of these mutations in ovarian cancer is rarely discussed in existing studies.…”

A comprehensive genomic meta-analysis identifies confirmatory role ofOBSCNgene in breast tumorigenesis

“…OBSCN gene is frequently and consistently mutated in various cancers with a strong correlation with breast, colorectal and other female related cancers. Recent studies revealed that TP53 and OBSCN genes are highly mutated among 189 candidate genes in breast and colorectal cancers [ 13 , 17 ]. However, scientific background on OBSCN mutation and its impacts are limited in comparison to the other key genes involved in breast cancer [ 18 , 19 ].…”